Arcus Biosciences, Inc.
US ˙ NYSE ˙ US03969F1093

Introduction

This page provides a comprehensive analysis of the known insider trading history of Tang Carolyn C.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Tang Carolyn C. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RCUS / Arcus Biosciences, Inc. General Counsel 137,623
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Tang Carolyn C.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases RCUS / Arcus Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in RCUS / Arcus Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RCUS / Arcus Biosciences, Inc. Insider Trades
Insider Sales RCUS / Arcus Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in RCUS / Arcus Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-12-16 RCUS Tang Carolyn C. 2,125 30.6600 2,125 30.6600 65,152 332 13.4300 -36,613 -56.20
2022-12-16 RCUS Tang Carolyn C. 398 31.2300 398 31.2300 12,430
2022-06-17 RCUS Tang Carolyn C. 449 21.7100 449 21.7100 9,748
2022-06-17 RCUS Tang Carolyn C. 1,073 22.2900 1,073 22.2900 23,917
2022-06-16 RCUS Tang Carolyn C. 1,400 20.7200 1,400 20.7200 29,008
2021-12-17 RCUS Tang Carolyn C. 138 38.7877 138 38.7877 5,353
2021-12-17 RCUS Tang Carolyn C. 88 39.6719 88 39.6719 3,491
2021-12-17 RCUS Tang Carolyn C. 171 40.5732 171 40.5732 6,938
2021-12-17 RCUS Tang Carolyn C. 225 41.4238 225 41.4238 9,320
2021-12-16 RCUS Tang Carolyn C. 356 39.5916 356 39.5916 14,095
2021-12-16 RCUS Tang Carolyn C. 131 40.4565 131 40.4565 5,300
2021-06-17 RCUS Tang Carolyn C. 1,606 23.6800 1,606 23.6800 38,030
2021-06-16 RCUS Tang Carolyn C. 1,257 24.1300 1,257 24.1300 30,331
2021-06-16 RCUS Tang Carolyn C. 52 24.7700 52 24.7700 1,288

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RCUS / Arcus Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Tang Carolyn C. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-27 2025-01-23 4 RCUS Arcus Biosciences, Inc.
Common Stock
A - Award 37,000 137,623 36.77
2024-12-17 2024-12-15 4 RCUS Arcus Biosciences, Inc.
Common Stock
F - Taxes -11,339 100,623 -10.13 16.08 -182,331 1,618,018
2024-06-18 2024-06-15 4 RCUS Arcus Biosciences, Inc.
Common Stock
F - Taxes -4,182 111,364 -3.62 16.97 -70,969 1,889,847
2024-01-25 2024-01-23 4 RCUS Arcus Biosciences, Inc.
Common Stock
A - Award 26,700 114,579 30.38
2023-12-20 2023-12-19 4 RCUS Arcus Biosciences, Inc.
Common Stock
D - Sale to Issuer -4,076 87,879 -4.43 18.09 -73,735 1,589,731
2023-12-20 2023-12-18 4 RCUS Arcus Biosciences, Inc.
Common Stock
D - Sale to Issuer -3,991 91,955 -4.16 17.74 -70,800 1,631,282
2023-06-16 2023-06-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
D - Sale to Issuer -2,892 95,902 -2.93 19.35 -55,960 1,855,704
2023-01-25 2023-01-23 4 RCUS Arcus Biosciences, Inc.
Common Stock
A - Award 34,000 97,539 53.51
2022-12-16 2022-12-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -398 28,584 -1.37 31.23 -12,430 892,678
2022-12-16 2022-12-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -2,125 28,982 -6.83 30.66 -65,152 888,588
2022-06-21 2022-06-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -1,073 23,909 -4.30 22.29 -23,917 532,932
2022-06-21 2022-06-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -449 24,982 -1.77 21.71 -9,748 542,359
2022-06-21 2022-06-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -1,400 25,431 -5.22 20.72 -29,008 526,930
2022-03-10 2022-03-08 4 RCUS Arcus Biosciences, Inc.
Stock Option (right to buy)
A - Award 65,000 65,000
2022-03-10 2022-03-08 4 RCUS Arcus Biosciences, Inc.
Common Stock
A - Award 16,250 33,814 92.52
2021-12-20 2021-12-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -225 17,564 -1.26 41.42 -9,320 727,568
2021-12-20 2021-12-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -171 17,789 -0.95 40.57 -6,938 721,757
2021-12-20 2021-12-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -88 17,960 -0.49 39.67 -3,491 712,507
2021-12-20 2021-12-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -138 18,048 -0.76 38.79 -5,353 700,040
2021-12-20 2021-12-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -131 18,186 -0.72 40.46 -5,300 735,742
2021-12-20 2021-12-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -356 18,317 -1.91 39.59 -14,095 725,199
2021-06-21 2021-06-17 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -1,606 15,362 -9.46 23.68 -38,030 363,772
2021-06-21 2021-06-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -52 16,968 -0.31 24.77 -1,288 420,297
2021-06-21 2021-06-16 4 RCUS Arcus Biosciences, Inc.
Common Stock
S - Sale -1,257 17,020 -6.88 24.13 -30,331 410,693
2021-01-20 2021-01-19 4 RCUS Arcus Biosciences, Inc.
Stock Option (right to buy)
A - Award 75,225 75,225
2021-01-20 2021-01-19 4 RCUS Arcus Biosciences, Inc.
Common Stock
A - Award 12,538 19,886 170.63
2020-12-18 3 RCUS Arcus Biosciences, Inc.
Common Stock
7,348
2020-12-18 3 RCUS Arcus Biosciences, Inc.
Common Stock
33,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)